DGAP-News: Paketeria AG: INJEX Pharma GmbH signed first contract with Kuwait in Middle East for sales of the innovative needle free drug delivery system INJEX30
(firmenpresse) - DGAP-News: Paketeria AG / Key word(s): Contract
Paketeria AG: INJEX Pharma GmbH signed first contract with Kuwait in
Middle East for sales of the innovative needle free drug delivery
system INJEX30
29.11.2011 / 11:03
---------------------------------------------------------------------
Paketeria AG
ISIN:DE000A0STYL7
Berlin, 29. November 2011
INJEX Pharma will start to deliver very soon the first shipment of their
needle free and painless syringe INJEX30 to the Middle East to Kuwait.
INJEX Pharma GmbH signed an exclusive distributor contract with Al SHAMALI
GROUP Co.( BOUBYAN MEDICAL ) from Sharq-Kuwait.
In Middle East the diabetes rate is among the highest in the world. The
people do not have enough exercise, people smoke, obesity is increased and
nutrition sweet and unhealthy. Africa, the Middle East and India have the
highest increasing prevalence worldwide.
The Al Shamali Group signed pre contracts for other countries in Middle
East. The registration for the product is expected short term. The
pharmaceutical division manager Dr. Wael A. Elghamri is responsible for the
market introduction.
Al-Shamali Group for General Trading&Contracting was established in
Kuwait City, the State of Kuwait in 1992. Over the past two decades it has
grown from its humble sole focus on construction to a very diverse group of
companies encompassing International Investment, Medical&Pharmaceuticals.'
Mr. Ali A. Reda, the General Manager for Al-Shamali Group Co. stated that
'INJEX is a unique instrument that will make a big difference and a relief
from needle shots for Diabetic patients in Kuwait and other countries in
the region. As one patient feedback after receiving and testing a starter
kit sample was 'IT IS MAGIC'
Dr. Wael A. Elghamri, Pharmaceutical Division Manager (Boubyan Medical),
stated: 'From our studying in our area diabetes rate is among the highest
in the world, we have more than 20% of population patients with diabetes,
more than 18% of them are insulin dependent. In addition we see other
treatments of INJEX30 like immunization, local anesthesia and meso -
therapy. So we expect very high sales at launch.'
Andy Rösch, CEO of Paketeria AG (INJEX Pharma AG): 'We are very convinced
that this agreement is just the very first step with the INJEX30, made in
Germany, into the Middle East Area. We have a lot of other interested
companies from Middle East, who are interested to market our needle free
syringe. Last week we trained directly after MEDICA our potential new
partner for Saudi Arabia and we expect the contract to be signed before
Christmas '
INJEX Pharma GmbH shall be merged by 100 % into Paketeria AG, listed at the
Frankfurt Stock Exchange, which is the main resolution on the Annual
Meeting of December 16th 2011 in Berlin. Paketeria AG will have the new
company name INJEX Pharma AG.
press contact:
Maysmedia
Am Ideck 28
D-42781 Haan
0049-2129-343439
germany(at)maysmedia.de
contact:
Andy Rösch
CEO / Managing Director
Paketeria AG / INJEX Pharma AG
Buckower Damm 114
12349 Berlin
Tel.: 030/53096768
andy.roesch(at)injex.de
www.injex.de
Dr. Ulrich Franz
Director of the Supervisory Board
Ulrich.franz(at)gmx.net
End of Corporate News
---------------------------------------------------------------------
29.11.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
147935 29.11.2011
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.11.2011 - 11:03 Uhr
Sprache: Deutsch
News-ID 91744
Anzahl Zeichen: 6348
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 374 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Paketeria AG: INJEX Pharma GmbH signed first contract with Kuwait in Middle East for sales of the innovative needle free drug delivery system INJEX30"
steht unter der journalistisch-redaktionellen Verantwortung von
Paketeria AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
